Ipsen

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 12:32:47 18/07/2024 BST			5-day change	1st Jan Change
110.6 ^EUR	-0.54%		-0.45%	+3.06%

07-11	CAC40: maintains gains after reassuring US inflation figures	CF
07-11	CAC40: rise without volume, W-Street at its zenith but falls back	CF

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

July 16, 2024 at 05:00 pm

Aggregated presentation by day and by market

Purchases of own shares from July 8th to 12th 2024

Name of the Issuer	Identity code of the Issuer	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	6 650	111,0282	XPAR
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	2 700	110,9397	CEUX
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	350	111,1231	TQEX
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	300	111,2180	AQEU
IPSEN	549300M6SGDPB4Z94P11	09/07/2024	FR0010259150	4 900	109,7478	XPAR
IPSEN	549300M6SGDPB4Z94P11	09/07/2024	FR0010259150	2 100	109,6744	CEUX
IPSEN	549300M6SGDPB4Z94P11	10/07/2024	FR0010259150	5 382	108,6341	XPAR
IPSEN	549300M6SGDPB4Z94P11	10/07/2024	FR0010259150	2 000	108,7151	CEUX
IPSEN	549300M6SGDPB4Z94P11	11/07/2024	FR0010259150	1 487	110,1258	XPAR
IPSEN	549300M6SGDPB4Z94P11	11/07/2024	FR0010259150	299	110,1107	CEUX
			TOTAL	26 168	109,9431

Attachment

EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 28_2024

Latest news about Ipsen

CAC40: maintains gains after reassuring US inflation figures	07-11	CF
CAC40: rise without volume, W-Street at its zenith but falls back	07-11	CF
CAC40: over 7600pts before US inflation figures	07-11	CF
Ipsen: worldwide licensing agreement with Foreseen	07-11	CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate	07-11	MT
Markets Powered by Alternating Current	07-10
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China	07-05	MT
Ipsen Expands Partnership with Exelixis for Cabometyx	07-02	MT
Ipsen extends collaboration with Exelixis	07-02	CF
IPSEN : UBS remains positive ahead of quarterly results	06-26	CF
Ipsen: share price soars, UBS confirms its recommendation	06-12	CF
IPSEN : UBS remains Buy after FDA approval	06-12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	06-11	CI
Ipsen: FDA grants approval for treatment	06-11	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	06-11	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	06-10	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	06-10	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	06-10	RE
US FDA approves Genfit and Ipsen's liver disease drug	06-10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	06-07	MT
Ipsen: research partnership with Marengo extended	06-07	CF
Ipsen Hires New Chief Corporate Affairs Officer	06-06	MT
Ipsen: new Chief Corporate Affairs Officer	06-06	CF
Ipsen: new positive data in PBC	06-05	CF
Ipsen: mandate to an ISP for share buybacks	06-03	CF

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 03:50 pm

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.2 EUR

Average target price

127.3 EUR

Spread / Average Target

+14.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+3.06%	10.04B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.36%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.49%	247B
NOVARTIS AG	+14.94%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals